At the same time, the higher gene expression levels of Kir2.1, Kir3.1, and a lower gene expression level of Cav1.2 were also represented in the OSA group, although these levels were not attenuated after LLVS was administered. This evidence concerns the gene KCNJ2 and obstructive sleep apnea syndrome.